Brokerages Expect Trevena Inc (TRVN) to Announce -$0.26 EPS

Brokerages expect Trevena Inc (NASDAQ:TRVN) to post earnings per share (EPS) of ($0.26) for the current quarter, Zacks reports. Zero analysts have provided estimates for Trevena’s earnings. The lowest EPS estimate is ($0.27) and the highest is ($0.24). Trevena reported earnings of ($0.67) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 61.2%. The business is expected to report its next earnings results on Wednesday, March 14th.

On average, analysts expect that Trevena will report full-year earnings of ($1.23) per share for the current financial year, with EPS estimates ranging from ($1.25) to ($1.21). For the next year, analysts anticipate that the business will report earnings of ($0.97) per share, with EPS estimates ranging from ($1.17) to ($0.82). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Trevena.

TRVN has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Trevena from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a report on Wednesday, October 18th. Needham & Company LLC cut their price target on shares of Trevena from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, November 8th. HC Wainwright cut their price target on shares of Trevena from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Thursday, October 12th. Barclays downgraded shares of Trevena from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $15.00 to $2.50 in a report on Monday, October 16th. Finally, Oppenheimer restated a “buy” rating and set a $5.00 price target on shares of Trevena in a report on Monday, November 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $7.35.

Large investors have recently bought and sold shares of the stock. Nationwide Fund Advisors grew its stake in Trevena by 92.1% in the 2nd quarter. Nationwide Fund Advisors now owns 49,132 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 23,557 shares during the last quarter. Alliancebernstein L.P. grew its stake in Trevena by 51.9% in the 2nd quarter. Alliancebernstein L.P. now owns 55,300 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 18,900 shares during the last quarter. Virtu KCG Holdings LLC grew its stake in Trevena by 144.0% in the 2nd quarter. Virtu KCG Holdings LLC now owns 58,660 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 34,618 shares during the last quarter. American Century Companies Inc. acquired a new position in Trevena in the 4th quarter valued at $135,000. Finally, Rhumbline Advisers grew its stake in Trevena by 30.1% in the 2nd quarter. Rhumbline Advisers now owns 64,251 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 14,880 shares during the last quarter. Institutional investors and hedge funds own 56.74% of the company’s stock.

Trevena (NASDAQ:TRVN) opened at $1.54 on Wednesday. The firm has a market cap of $94.70, a price-to-earnings ratio of -0.93 and a beta of -0.51. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.92 and a current ratio of 4.92. Trevena has a twelve month low of $1.35 and a twelve month high of $8.00.

TRADEMARK VIOLATION WARNING: “Brokerages Expect Trevena Inc (TRVN) to Announce -$0.26 EPS” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/07/brokerages-expect-trevena-inc-trvn-to-announce-0-26-eps.html.

Trevena Company Profile

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Get a free copy of the Zacks research report on Trevena (TRVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply